Fig. 3: MAb 3H4 enhanced the cytotoxicity of the NKG2A + NK cell line NK-92 against HLA-E-VL9-expressing 293T cells.
From: Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity
a Schematic illustrating the hypothesis. Blockade of the inhibitory NKG2A/CD94/HLA-E pathway with anti-HLA-E-VL9 antibody (3H4) and/or anti-NKG2A antibody (Z199) could enhance target cell lysis by NK cells. b, c NK cell cytotoxicity against 3H4 IgM-treated target cells as assessed by 51Cr release assay. Antibody was incubated with HLA-E-VL9-transfected 293T cells (b) and untransfected 293T cells (c) at final concentration of 10 μg/ml or 3 μg/ml, and NK92 cells were added into the mixture as effector cells at effector: target (E:T) ratios of 20:1 and 6:1. Mouse IgM MM-30 was used as an isotype controls. Dots represent the mean values of triplicate wells in eight independent experiments. Statistical analysis was performed using mixed effects models. Asterisks show the statistical significance between indicated groups: ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. d, e NK cell cytotoxicity in the presence of anti-NKG2A mouse IgG Z199 in combination with TE4 control- or 3H4-treated target cells as assessed by 51Cr release assay. Antibody combinations of Z199 + IgM control (d) or Z199 + 3H4 (e) were incubated with HLA-E-VL9-transfected 293T cells and untransfected 293T cells at a final concentration of 10 μg/ml, and NK92 cells were added into the mixture as effector cells. Dots represent the mean values of triplicate wells in three independent experiments.
